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AbstrAct
There are increasing needs for detailed real-world data 
on rheumatic diseases and their treatments. Clinical 
register data are essential sources of information that can 
be enriched through linkage to additional data sources 
such as national health data registers. Detailed analyses 
call for international collaborative observational research 
to increase the number of patients and the statistical 
power. Such linkages and collaborations come with legal, 
logistic and methodological challenges. in collaboration 
between registers of inflammatory arthritides in Sweden, 
Denmark, Norway, Finland and iceland, we plan to enrich, 
harmonise and standardise individual data repositories to 
investigate analytical approaches to multisource data, to 
assess the viability of different logistical approaches to 
data protection and sharing and to perform collaborative 
studies on treatment effectiveness, safety and health-
economic outcomes. This narrative review summarises 
the needs and potentials and the challenges that remain 
to be overcome in order to enable large-scale international 
collaborative research based on clinical and other types of 
data.
The need for real-world daTa from 
paTienTs wiTh inflammaTory joinT diseases
With a prevalence of 1%–2% in the general 
population and lifetime risks of at least 1 in 20, 
chronic inflammatory joint diseases including 
rheumatoid arthritis (RA), ankylosing spon-
dylitis (AS), other spondyloarthritides (SpA), 
including psoriatic arthritis (PsA), represent 
a significant burden for afflicted individ-
uals, for healthcare and for society at large, 
whether measured as pain, functional impair-
ment, healthcare resource utilisation or costs.
The therapeutic approaches to chronic 
inflammatory joint diseases have changed 
substantially over the last two decades. A 
growing number of treatment options have 
enabled increasingly ambitious treatment 
goals, but also lead to complex treatment 
patterns and concerns regarding their costs. 
To determine the optimal treatment in the 
clinical setting, including its value for the 
individual and for society, studies assessing 
effectiveness, safety and long-term outcomes 
of different treatment options in different 
treatment contexts are necessary. A better 
understanding of the heterogeneities, comor-
bidities and societal outcomes of the treated 
diseases themselves is also required to enable 
individualised treatment.
Randomised controlled trials (RCTs), while 
still the gold standard for efficacy studies, 
often provide insufficient evidence to inform 
Key messages
 ► There is increasing need for detailed real-world 
data on rheumatic diseases and their treatments.
 ► This need goes beyond clinical data and calls for 
enrichment of data in the clinical registers through 
linkages to other data sources and for collaborative 
observational research across national borders.
 ► Such enrichment and collaboration come with legal, 
logistic and methodological challenges.
 ► Through collaboration between rheumatology 
registers on chronic inflammatory arthritides in 
Sweden, Denmark, Norway, Finland and iceland, 
we hope to address these challenges and to 
study treatment effectiveness, safety and health-
economic outcomes in rheumatoid arthritis, axial 
spondyloarthritis and psoriatic arthritis.
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clinical practice as their size, strict inclusion and exclu-
sion criteria, restricted treatment options and follow-up 
times typically preclude inferences regarding the long-
term safety and effectiveness. Furthermore, RCTs have 
limited power to provide safety evidence with regard to 
rare events and the performance of treatment of patients 
not fulfilling the entry criteria for RCTs. Thus, some of 
the clinically most relevant questions are virtually impos-
sible to address in a randomised controlled setting.
For all of the above reasons, we are increasingly facing 
situations where large-scale observational studies based 
on real-world data are needed. To this end, clinical 
rheumatology registers have been established in many 
countries, either as disease registers, such as an early RA 
register, or as registers to specifically monitor treatment, 
such as a biologics register, or as both.1–5 Rheumatology 
has been at the forefront in establishing population based 
regional or national longitudinal clinical disease registers 
(in the Scandinavian countries: SRQ/ARTIS, DANBIO, 
NOR-DMARD, ROB-FIN and ICEBIO). Detailed infor-
mation about each of these clinical rheumatology regis-
ters has been published previously1 6–12 and summarised 
in table 1.
The need for enriChing CliniCal regisTer daTa Through 
linkage To oTher regisTers
Clinical registers provide a potential for large-scale data 
at a level of clinical detail (eg, specific clinical metrics, 
such as Disease Activity Score 28) that is often much 
higher than that found in administrative or claims data. 
Similarly, clinical registers may provide a unique source 
for patient-reported outcome measures (PROMs) data. 
To be sustainable in the long run, clinical data collection 
for a register needs to be slim enough to fit (and benefit) 
clinical practice. Conversely, there is a limit with regard 
to the amount and nature of information that lends itself 
to collection in the clinical setting. While clinical regis-
ters are ideal to collect information that are also rele-
vant and available at the clinical visit, clinical registers 
are often not the ideal vehicle for the collection of rare 
and unexpected events or factors that ‘occur’ outside of 
rheumatology (ie, may not be known to the rheumatol-
ogist, such as cost data) or for events for which there is 
considerable recall bias. For these latter types of events, 
obtaining data from other data sources can both bring 
down the burden of data collection in the clinical register 
and offer ‘objective’ measurements devoid of subjectivity 
(eg, cost, or work ability) or recall bias (eg, drug prescrip-
tion data), at a high level of completeness.
In settings with other national registers available, such 
as in the Nordic countries, the clinical rheumatology 
registers may be enriched via linkages to such other popu-
lation-based registers and ‘complete’ registers. Examples 
of such are registers on cancer incidence, mortality or 
work force participation. Existence of personal identifiers 
enables deterministic record linkage. Table 2 outlines 
different types of external data sources in each of the 
Nordic countries which are possible to link to the clinical 
rheumatology registers. As evident from the table, such 
linkages entail considerable administrative preparation, 
with approval from multiple authorities and a waiting 
time varying between several months and more than a 
year. Importantly, linkage to external register holders 
often puts additional restrictions on what the linked data 
may be used for, how they can be accessed and whether 
(if physically accessible) they may be exported. All of 
these processes and restrictions vary across country, to 
some extent across different public register holders 
within each country and also over time. Currently, there 
is no such thing as a ‘push-the-button’ mechanism to link 
all clinical data to all of the national data sources listed 
in table 2. Rather, work in this field still relies on prac-
tical experience from each of the registers and register 
holders’ modus operandi.
Linkage to external data sources offers additional 
benefit, namely, the possibility to assemble general 
population, or disease-specific comparator cohorts. For 
instance, for every individual in the clinical register, 10 
(or 100 or 1000) general population comparator subjects 
may be sampled and then subjected to additional register 
linkages. Such a general population cohort will provide 
the possibility to contextualise any differences in risk 
among patients with a certain disease (say, treated with X 
instead of Y) to any risks associated with merely having (vs 
not having) the disease at all. Compare, for instance, the 
large increase in risk of tuberculosis in biologics-treated 
RA versus biologics-naive RA versus the only moderate 
risk increase of tuberculosis in biologics-naive RA versus 
the general population, or any marginal risk increase of 
malignant lymphomas in tumour necrosis factor inhibi-
tors (TNFi)-treated versus TNFi-naive RA versus the clear 
increase in lymphoma risk in biologics-naive RA versus 
the general population.13–15
The need for CollaboraTive observaTional sTudies 
and The need for daTa harmonisaTion
In a number of situations, collaboration across registers is 
necessary. For instance:
1. Studies of rare treatment exposures.
2. Studies of rare outcomes.
3. Studies at a maximal phenotypic resolution, 
acknowledging that individualised treatment rather 
than treatment on average should not only focus on 
the treatment but also on the characteristics of the 
treated disease, a fact that rapidly decreases statistical 
precision in the specific subset of individuals with 
those characteristics.
While collaborative studies are increasingly needed, 
they come with specific challenges, at several levels. A 
proactive approach to these challenges is absolutely vital 
for the success and interpretability of the outcome of any 
collaborative study.
First, there is heterogeneity in the primary clinical 
data collection in the clinical registers in terms of what is 
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collected and how it is defined and collected.16 Harmon-
isation at this level can result in changes in the primary 
data collection, or in its subsequent coding or categori-
sation. Examples of such harmonisation efforts include 
the European League Against Rheumatism (EULAR) 
Task Force on RA data collection in clinical practice.17 
It should be pointed out that harmonisation does not 
mean that all registers need to collect the same and 
only the same variables, only that core elements of the 
data collection should be defined in a way that ensures 
Table 1 Overview of the five Nordic clinical rheumatology registers
Sweden Denmark Norway Finland Iceland
Name SRQ/ARTIS DANBIO NOR-DMARD ROB-FIN ICEBIO
First established 1990 2000 2000 1999 2007
Target population Initially an early RAs 
and a biologics-
register, later 
opened to all 
inflammatory joint 
diseases
Initially a 
biologics 
register, since 
2005 open to 
all inflammatory 
joint disease 
regardless of 
treatment
A multicenter 
biologic register 
for rheumatic 
disorders
A nationwide 
biologic register 
for rheumatic 
disorders
A nationwide 
biologic register 
for rheumatic 
disorders
Data collection Web-based 
reporting at (dr/
pt) or before (pt) 
routine clinical visits
Web-based 
reporting by 
patient (PROMs) 
and doctor at 
routine clinical 
visits
Web-based 
reporting by 
patient (PROMs) 
and doctor at 
routine clinical 
visits
Web-based 
reporting by 
patient (PROMs) 
and doctor at 
routine clinical 
visits
Web-based annual 
reporting (dr/pt) 
at routine clinical 
visits
Types of data collected Disease activity 
and antirheumatic 
treatment
Disease activity 
and antirheumatic 
treatment
Disease activity 
and ant-rheumatic 
treatment
Disease activity 
and antirheumatic 
treatment
Disease activity, 
biologics and 
antirheumatic 
treatment
Coverage (RA) Around 80% 80%–90%33 95%
Patients in the register (ever)
  All 88 089 58 700 11 537 24 000 1675
  RA 50 080 32 200 5266 10 900 645
  Ankylosing spondylitis
  /spondyloarthritides 
9941 4100 2291 2789 340
  Psoriatic arthritis 12 269 9100 2312 2270 420
  Other diagnoses 15 799 13 300 1668 8041 270
Biologic disease-modifying 
antirheumatic drug treatment starts
  Etanercept 16 603 10 700 2438 4190 690
  Adalimumab 13 283 8400 1617 3656 270
  Infliximab 11 941 9300 906 2230 1285
  Certolizumab pegol 3337 2800 1500 531 <10
  Golimumab 4621 2300 867 927 205
  Abatacept 3364 1600 136 572 15
  Rituximab 6300 1900 407 1180 90
  Tocilizumab 3242 2300 230 463 95
  Secukinumab 730 282 45 0 25
  Apremilast 459 15 0 210 <10
  Any tumour necrosis 
factor inhibitors 
biosimilar
8619 7400 690 180 525
Diagnoses and treatments currently covered.
dr, doctor; PROM, patient-reported outcome measures; pt, patient; RA, rheumatoid arthritis
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comparability or translatability across registers. Hetero-
geneity regarding population background risks between 
countries has also to be taken into account. A good 
example is the recent collaborative analyses on malig-
nant melanomas and lymphomas under the umbrella of 
EULAR.18
Table 2 Examples of enrichment that can be enabled via linkages of the clinical rheumatology registers to other national and 
population-based registers
Sweden Denmark Norway Finland Iceland
Population (million) 10.1 5.7 5.6 5.5 0.3
Conditions for register linkages
  Individual 
informed consent
Generally not for 
register-only studies
Not for 
epidemiological 
research
Depending on 
Ethics Review 
Board assessment 
of individual 
projects
Not for register 
studies by 
permission from the 
National Institute for 
Health and Welfare 
ad 2020
Not for 
epidemiological 
research
  Approvals
Ethics Review 
Board, approval 
from each register 
holder
Approval from the 
data protection 
agency and from 
registry holder
Ethics Review 
Board, approval 
from each register 
holder
Ethics Review 
board and the 
National Institute for 
Health and Welfare
Approval from the 
National Bioethics 
Committee, Data 
Protection Authority 
and from registry 
holders
  Time from 
application to 
data delivery 6–12 months <6 months 6–12 months 12 months <6 months
Information
Hospitalisations, 
in-patient care
The Swedish 
Patient Register 
1987
The National Patient 
Registry 1977
The Norwegian 
Patient Register 
2008
Hospital Finnish 
Discharge Register 
1998
The Icelandic 
National Patient 
Registry 1999
Outpatient visits in 
specialised care
The Swedish 
Patient Register 
2001
The National Patient 
Registry 1995
The Norwegian 
Patient Register 
2008
Hospital discharge 
register 1998 No
Primary care
Yes, for three 
regions (50% of 
country) No No No No
Vital status, 
residency, civil 
status
The Population 
Register: 1962
The Civil 
Registration System 
1968
The National 
Registry: 1946
Population register 
(date of death) 1969
The Population 
Register 1914
Cause of death
The Death Register 
1952
The Causes of 
Death Registry 
1943
The Cause of Death 
Registry 1951 No
The Causes of 
Death Registry 
1971
Cancer
The Cancer 
Registry 1958
The Cancer 
Registry 1942
The Cancer 
Registry 1951
The Cancer 
Registry 1952
The Cancer 
Registry 1954
Prescribed drugs
The Prescribed 
Drug Register 2005
The Danish 
National Database 
of Reimbursed 
Prescriptions 2004
The Prescription 
Database 2004
Co-payment 
register 2007
The Medicinal 
Dispense Registry 
2002
Education and 
occupation
The Education 
Register 1960
Dutch Rheumatoid 
Arthritis Monitoring 
Registry 1991
The National 
Education Database 
1970 No No
Sick leave, disability 
pension
The Social 
Insurance Agency 
Register (MIDAS) 
1992 and LISA 
1990 IDA registry 1980
The Labour 
and Welfare 
Administration 2008
The registers 
for sick leaves, 
pensions and 
rehabilitation 2000
The Social 
Insurance 
Administration 1997
LISA, Longitudinal Database for health insurance and labor market studies; MiDAS, Swedish Social Insurance Agency’s database Micro Data 
for Analysis of Social Insurance. 
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Second, enrichment of the raw data in a clinical register 
through linkage to external registers should be compa-
rable. Since such external data sources (eg, a national 
cancer register) are seldom amenable to changes in their 
primary data collection, harmonisation at this level will 
largely be about harmonising algorithms with which 
these data are curated. For instance, in a multicountry 
drug safety study of myocardial infarction using linkage 
of clinical RA treatment data to hospital data on myocar-
dial infarction, harmonisation may be about defining 
what is meant by a ‘myocardial infarction’ in each of 
these hospital registers. ‘Myocardial infarction’ may, for 
instance, comprise various combinations of unstable 
angina, ST-segment elevation and non ST-segment eleva-
tion infarctions and include or exclude sudden cardiac 
death.
Third, also the analytical protocols need to be harmon-
ised. In the above example of myocardial infarction, 
such harmonisation will ensure that, for instance, the 
risk windows during which each study subject is consid-
ered to be at risk for a myocardial infarction following 
a specific antirheumatic treatment are the same across 
all participating sites or countries, or that adjustment 
for demographics and comorbidities are performed in a 
comparable manner across sites or countries. Harmonisa-
tion at this level will require a reasonably detailed under-
standing of the data to be included and must therefore 
be a joint effort across all collaborators.
Even with perfect harmonisation, not all data sources 
may provide information on all the desired variables, a 
fact that effectively may preclude identical analyses to 
be performed. For instance, say that Register I holds 
information on covariates A, B and C, Register II holds 
information on covariates A, B, D but not C, and Register 
III holds information on A, C, E but neither B nor D 
(figure 1). To run one and the same model across these 
three registers would mean a model only containing 
variable A. Within each register, however, more elabo-
rate models (each including three co-covariates) can 
be run. The trade-off here is whether it is preferable to 
let each register come up with its own ‘best’ model and 
apply meta-analytic techniques to weigh these ‘best’ esti-
mates together even if the collation of relative risks across 
registers will no longer mean combining risk estimates 
from identical models, or whether a joint analysis based 
on fewer but identical covariates is the better choice. In 
situations where A, B, C, D and E above all represent 
aspects of the same item (say, treatment response and 
that A=EULAR DAS28 response, B=ACR response and so 
on) then one way forward may be to create a new vari-
able (‘response’) and have each register categorise indi-
viduals into responders or non-responders according to 
the response-metric captured in each register. Another 
analytical challenge occurs when the relative importance 
of a covariate, such as obesity, on an outcome, such as 
cardiovascular risk, varies across registers.
Finally, treatment channelling, or confounding by 
indication, is an important aspect of all observational 
comparative effectiveness or safety research, collabora-
tive or not. It reflects the fact that treatment allocation in 
clinical practice is not a random process, but determined 
by known and unknown factors related to the patient, to 
his or her rheumatic disease and other medical history, 
the treating physician and the treatment context. While 
there is no single method that effectively quantifies and 
eliminates confounding by indication, judicious analyses 
informed by hands-on experience from the very clinical 
practice that gave rise to the data at country level or at 
regional level within each country and by access to indi-
vidual-level data beyond clinical data (such as data on 
socioeconomy) can help demonstrate the extent to which 
channelling is present. Different analytical techniques 
can be used to reduce its impact. When confounding 
by indication is likely to differ in magnitude (or even 
direction) across countries, harmonised but parallel 
analyses provide an opportunity for an assessment of 
the importance of confounding by indication, while 
also adding a point to the analysis plan as some variables 
may be completely necessary to adjust for in some coun-
tries, but of less importance in others. Epidemiologists 
need to consider differential selection bias by country 
when analysing multiregional data. The best method 
to combine data from various registries will therefore 
depend on the research question, the outcome, the pres-
ence of effect modification by country and the need of 
higher statistical power.
TeChniCal, logisTiC and legal Challenges in 
CollaboraTive sTudies: Can and should daTa Travel?
After agreeing on a specific research question, collabora-
tion between different registers can conceptually include 
different approaches (figure 2):
1. Analyses based on exports of harmonised, anonymised 
or de-identified, individual-patient level data from 
each register to a central database, where they are 
collated and analysed jointly as one data set.
2. Fully federated analyses, in which the curated individ-
ual-level data are analysed from a central unit and as 
one virtual data set, yet do not leave the local servers 
where they are stored.
3. Separate but harmonised analyses of curated data, 
conducted in parallel at each register. The curated 
data sets are analysed individually in each country 
Figure 1 Illustration of the challenge residing in only partial 
overlaps in the primary data collection across registers, with 
only variable A as common across registers.
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based on a harmonised analysis protocol, with the 
results presented both individually per register and 
pooled through meta-analytic techniques.
There are advantages and drawbacks with each of the 
above alternatives. Currently, and as outlined above, cross-
border transfer of data are often accompanied by uncer-
tainties or bureaucratic bottlenecks regarding legal and 
logistic aspects of handling of the data and export across 
borders. Often, these are questions beyond the control of 
the individual researcher. Still, there are a series of exam-
ples that demonstrate the feasibility of this approach, 
at least for collaborations built exclusively around clin-
ical register data.19–22 It should be pointed out that even 
anonymised or de-identified data may, by virtue of their 
richness, be personal data and have to be treated accord-
ingly. The European Union (EU) General Data Protec-
tion Regulation does not seem to substantially alter the 
underlying premises for performing research based on 
register data or register linkages or the movement of data 
within EU countries, at least not from a northern Euro-
pean point of view, but this remains an important issue 
for close monitoring.23
While intuitively appealing, fully federated analyses 
(option 2) are linked to issues of whether, from a legal 
point of view, providing external access to the data is 
any different from exporting the very same data to the 
analysing party. If the analyses are run ‘in the cloud’, then 
some sort of data export must de facto have occurred. 
There are, however, promising technical solutions in 
operation that rely on transfer of scripts and interim 
results (aggregate-level data or parameter estimates) 
only, and thereby circumvent the challenge of actual 
or virtual data access and transfer.24 25 Running models 
that are based on iterative model-building across several 
data sets may, however, be time-consuming and limited by 
the information-transfer capacities in the network used.
By contrast, separate but harmonised analyses (option 
3) put particular demands on harmonisation not only of 
the raw data but also of the statistical analysis plan to be 
executed at each register. Since the absence of pooling of 
individual-level data precludes the potential for adjusted 
analyses across data sets, other means to accommodate 
important risk determinants across data sets must be 
implemented (eg, stratification and standardisation, 
as exemplified in a recently published study26). The 
analytical ‘output’ to be pooled through meta-analytic 
approaches may vary from rates to actual relative risk esti-
mates. Since all programming and analysis would need to 
Figure 2 Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data 
sources within each of the five Nordic countries and various approaches to collaboration across the five Nordic countries.
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be run separately at each collaborating site, this option 
also may also require more total work hours than the 
other options, where at least the central analysis would 
only need to be run by one designated statistician.
a nordiC iniTiaTive To faCiliTaTe CollaboraTion aCross 
enriChed rheumaTology regisTers
With largely similar healthcare structures, the existence 
of national registers on medical and societal outcomes 
(cancer, hospitalisations, pregnancies, sick leave, other 
cost reimbursements and so on) and the possibility to link 
information across registers, the premises for collaborative 
large-scale register-based research including enriched clin-
ical data are good across the Nordic countries, though not 
without challenges as those outlined above.
We have initiated a collaboration between the Nordic 
Rheumatology registers which aims to establish a standing 
network across Sweden, Denmark, Finland, Norway and 
Iceland for register research on patients with RA, AS, 
SpA and PsA. Taking a pragmatic and research-ques-
tion–based approach, we will exploit various approaches 
to harmonise (1) primary data collection, (2) data 
management and (3) analytical protocols, and to address 
legal, logistic and technical challenges involved in data 
handling and in data sharing, both with regard to the 
clinical register data and to linked data from other data 
sources (figure 2).
The research questions that can be addressed through 
a collaboration such as ours can largely be divided into 
two categories: (1) questions that can be addressed using 
the clinical registers only (eg, a clinical effectiveness 
study of response to treatment X vs response to treatment 
Y) and (2) questions that can typically only be addressed 
using data enriched with data from other sources data 
(eg, long-term malignancy risks with treatment Z). A 
logical first step before embarking on specific compar-
ative effectiveness/safety projects is to characterise and 
compare the patient populations across countries27 and 
to assess the relative uptake of different therapies in each 
country.27 28 Even with the similarities across the Nordic 
countries, heterogeneity is to be expected. Harmonisa-
tion of clinical input data is therefore a prerequisite, both 
regarding the definition and the collection, as well as of 
the study protocol. For each specific subproject launched 
within our collaboration, a prespecified statistical analysis 
protocol must be agreed on, and exposure, outcome and 
covariates need to be clearly defined. Besides study-spe-
cific definitions and analysis plans, this work will eventu-
ally result in a library of ‘standard’ and generic definitions 
for data harmonisation regardless of specific research 
question.
So far, our collaboration has begun to demonstrate 
similarities and differences across the Nordic countries 
with regard to biological therapies used in AS/SpA28and 
PsA29 and in the choice of biological therapies in patients 
with a history of cancer.30 Ongoing projects include 
studies of infection risks with newer type of biologics in 
RA, risks for demyelinating events with TNFi31 and birth 
outcomes.32
ConClusion
There is an increasing need for detailed real-world data 
on rheumatic diseases and their treatments in large 
patient populations. Collaboration across large, popu-
lation-based clinical rheumatology registers in settings 
that allow for enrichment through linkages to additional 
sources of information represent a powerful next step 
in the generation of real-world evidence and can be of 
great value for patients, clinicians, regulators, pharma-
ceutical companies and other healthcare providers. In 
this regard, the premises for register-based collaborative 
clinical research in the field of chronic inflammatory 
diseases in the Nordic countries are particularly prom-
ising. Such collaboration comes, however, with legal, 
logistic and methodological challenges. In a collabora-
tion between rheumatology registers on chronic inflam-
matory arthritides in the Nordic countries, we hope to 
enrich, harmonise and standardise the resultant data 
repositories to investigate analytical approaches to data 
coming from different sources, to assess the merits of 
different logistical approaches to data protection and 
sharing by performing collaborative studies on treatment 
effectiveness, safety and health-economic outcomes.
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